Gain insight on how genetics may impact medications
Learn more about the GeneSight® test
What is the GeneSight test?
GeneSight Psychotropic is a pharmacogenomic test which means that it analyzes how your genes may affect medication outcomes. The GeneSight test analyzes clinically important genetic variations in your DNA. Results can inform your healthcare provider about how you may break down or respond to certain medications commonly prescribed to treat depression, anxiety, ADHD, and other psychiatric conditions.
The GeneSight test must be ordered by your healthcare provider or nurse practitioner. The test is a simple cheek swab taken in your healthcare provider’s office or can be sent by your healthcare provider to be taken in the convenience of your home.
See the GeneSight test process
3,000,000+ people have taken the GeneSight test
Cost shouldn’t be a barrier
If you have insurance, we will bill your insurance for the cost of the GeneSight test. Some insurance plans will cover the cost though this can vary.
| Insurance type | Typical Cost |
|---|---|
| Medicare (part B) | $0 out of pocket |
| Medicaid | $0 out of pocket |
| Medicare advantage (part C), commercial or other | $330 or less |
| Uninsured | $330* or less |
*Reduced self-pay cost
A comprehensive report, personalized for you
The GeneSight test report may help you avoid multiple medication trials by providing information about which medications may require dose adjustments, be less likely to work, or have an increased risk of side effects based on your genetic information.
The report also includes information on how a patient’s smoking status may affect their body’s metabolism of certain medications.
- Use as directed
- Moderate gene-drug interaction
- Significant gene-drug interaction
The report classifies over 60 mental health medications into three categories.
The GeneSight test results do not provide information on disease diagnosis, medication allergies, drug-drug interactions, or which medications will work best.
Backed by extensive research
7 clinical studies published in peer-reviewed journals support the GeneSight test’s effectiveness.
GUIDED clinical study
The largest patient and rater blinded pharmacogenomic study in mental health.1
Key findings
The GeneSight test outperformed treatment as usual.
relative improvement in depressive symptoms2
relative improvement in response rates3
relative improvement in remission rates4
The GeneSight test process
The GeneSight test is administered by your healthcare provider in their office or at the comfort of your own home.
Click an icon to learn more.
Collection
Your provider collects a DNA sample by painlessly swabbing the inside of your cheek OR you can collect the sample at home using our patient collection kit.
Lab
The sample is sent to our lab for analysis.
Results
After we receive your sample, your healthcare provider will typically get test results in about 2 days.
Consultation
Your provider can contact our Medical Affairs team for a consultation. Your provider can then review the results with you on your next visit.
The stories shared on this page are individual patients’ personal experiences with GeneSight. Others may not have the same experience or outcome. Do not make any changes to your current medications or dosing without consulting your healthcare provider. The GeneSight test must be ordered by and used only in consultation with a healthcare provider who can prescribe medications.
Take the next step with the GeneSight test
Take a step closer to getting the GeneSight test or registering to provide the test to your patients. We will follow up with additional information either via email or phone.
The GeneSight test must be ordered by a registered clinician. If you are a patient, caregiver or office staff who would like a clinician to be registered to administer the GeneSight test, please include their name and contact information.
If you are a current registered provider or tested patient, please contact us.
Take the Next Step - PD
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Take the Next Step” page you agree to the possible transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be utilized for the sole purpose it was submitted for and governed by our Privacy Notice.
*Based on a review of six months of past claim data for major insurance carriers across the US. Last updated 2023.
- The GUIDED Clinical Study was an 8-week, blinded, randomized controlled trial of 1,167 subjects with major depressive disorder from 20 academic sites and 40 community sites.
- The primary endpoint of symptom improvement did not achieve statistical significance (p=0.107). Absolute improvement of 3%.
- Secondary endpoint of response achieved statistical significance (p=0.013). Absolute improvement of 6%
- Secondary endpoint of remission achieved statistical significance (p=0.007). Absolute improvement of 5%
